Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Metastatic Prostate Cancer: Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Metastatic...
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase II for Castration-Resistant...
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Hormone-Sensitive...
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Neuroendocrine Cancer: Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase I for Neuroendocrine...